HK1182029A1 - Conjugates for the prevention or treatment of nicotine addiction - Google Patents
Conjugates for the prevention or treatment of nicotine addictionInfo
- Publication number
- HK1182029A1 HK1182029A1 HK13109500.9A HK13109500A HK1182029A1 HK 1182029 A1 HK1182029 A1 HK 1182029A1 HK 13109500 A HK13109500 A HK 13109500A HK 1182029 A1 HK1182029 A1 HK 1182029A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- conjugates
- prevention
- treatment
- nicotine addiction
- addiction
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35134210P | 2010-06-04 | 2010-06-04 | |
PCT/IB2011/052446 WO2011151807A1 (en) | 2010-06-04 | 2011-06-03 | Conjugates for the prevention or treatment of nicotine addiction |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1182029A1 true HK1182029A1 (en) | 2013-11-22 |
Family
ID=44343221
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13109500.9A HK1182029A1 (en) | 2010-06-04 | 2013-08-13 | Conjugates for the prevention or treatment of nicotine addiction |
HK16102070.1A HK1214250A1 (zh) | 2010-06-04 | 2016-02-24 | 用於預防或治療煙碱成癮的綴合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16102070.1A HK1214250A1 (zh) | 2010-06-04 | 2016-02-24 | 用於預防或治療煙碱成癮的綴合物 |
Country Status (21)
Country | Link |
---|---|
US (2) | US8980276B2 (es) |
EP (1) | EP2575893A1 (es) |
JP (2) | JP5723976B2 (es) |
KR (1) | KR101429413B1 (es) |
CN (2) | CN102933237B (es) |
AR (1) | AR081299A1 (es) |
AU (1) | AU2011262221B2 (es) |
BR (1) | BR112012031360A2 (es) |
CA (1) | CA2800882C (es) |
CO (1) | CO6650413A2 (es) |
HK (2) | HK1182029A1 (es) |
IL (1) | IL223279A0 (es) |
MX (1) | MX342680B (es) |
MY (1) | MY158200A (es) |
NZ (1) | NZ603819A (es) |
PE (1) | PE20130232A1 (es) |
RU (1) | RU2574032C2 (es) |
SG (1) | SG186090A1 (es) |
TW (2) | TWI455722B (es) |
WO (1) | WO2011151807A1 (es) |
ZA (1) | ZA201300079B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
NZ593220A (en) * | 2008-12-09 | 2012-10-26 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
EP2917183A1 (en) | 2012-11-12 | 2015-09-16 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
CN105517555A (zh) * | 2013-09-05 | 2016-04-20 | 免疫设计股份有限公司 | 针对药物成瘾的疫苗组合物 |
US9303013B2 (en) * | 2014-05-16 | 2016-04-05 | Pfizer Inc. | Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction |
AU2015264325B2 (en) * | 2014-05-19 | 2019-02-14 | The Scripps Research Institute | Enantiopure haptens for nicotine vaccine development |
CN106496309A (zh) * | 2016-11-24 | 2017-03-15 | 北京开景基因技术有限公司 | 微球抗原及其制备方法以及抗可替宁抗体的制备方法 |
US11278608B2 (en) | 2017-01-05 | 2022-03-22 | Virginia Tech Intellectual Properties, Inc. | Nicotine nanovaccines and uses thereof |
WO2020176791A1 (en) * | 2019-02-28 | 2020-09-03 | Nano Vape Corporation | Nitric oxide releasing vaping formulations, compounds, use, and methods of forming |
CN118161604A (zh) * | 2024-03-25 | 2024-06-11 | 海南大学 | 一种尼古丁蛋白缀合物、其制备方法及在疫苗中的应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2315314A (en) * | 1941-06-10 | 1943-03-30 | Tobacco By Products And Chemic | Nicotine derivative |
US3964482A (en) | 1971-05-17 | 1976-06-22 | Alza Corporation | Drug delivery device |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
JPH02219595A (ja) * | 1988-09-02 | 1990-09-03 | Matsushita Electric Ind Co Ltd | ハプテンである抗原に対し高親和性を持つ抗体 |
US5015741A (en) | 1989-10-03 | 1991-05-14 | Philip Morris Incorporated | Nicotine analogs |
US5876727A (en) * | 1995-03-31 | 1999-03-02 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
SE9801923D0 (sv) * | 1998-05-29 | 1998-05-29 | Independent Pharmaceutical Ab | Nicotine vaccine |
US6503231B1 (en) | 1998-06-10 | 2003-01-07 | Georgia Tech Research Corporation | Microneedle device for transport of molecules across tissue |
US6232082B1 (en) * | 1998-12-01 | 2001-05-15 | Nabi | Hapten-carrier conjugates for treating and preventing nicotine addiction |
US6611707B1 (en) | 1999-06-04 | 2003-08-26 | Georgia Tech Research Corporation | Microneedle drug delivery device |
US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
SE0000933D0 (sv) * | 2000-03-21 | 2000-03-21 | Independent Pharmaceutica Ab | Method of producing 6-substituted (S)-nicotine derivatives and intermediate compounds |
US6277855B1 (en) | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
US6494844B1 (en) | 2000-06-21 | 2002-12-17 | Sanarus Medical, Inc. | Device for biopsy and treatment of breast tumors |
GB0017999D0 (en) | 2000-07-21 | 2000-09-13 | Smithkline Beecham Biolog | Novel device |
EP1345646A2 (en) | 2000-12-14 | 2003-09-24 | Georgia Tech Research Corporation | Microneedle devices and production thereof |
GB0031079D0 (en) | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Vaccine |
AU2002251821A1 (en) | 2001-01-26 | 2002-08-06 | The Scripps Research Institute | Nicotine immunogens and antibodies and uses thereof |
US6767341B2 (en) | 2001-06-13 | 2004-07-27 | Abbott Laboratories | Microneedles for minimally invasive drug delivery |
US6745211B2 (en) | 2001-11-21 | 2004-06-01 | Ge Financial Assurance Holdings, Inc. | Method and system for verifying and correcting data records in a database |
WO2003082329A2 (en) | 2002-03-01 | 2003-10-09 | The Board Of Regents Of The University Of Nebraska | Compositions and compounds for use as molecular adjuvant for a nicotine vaccine |
US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
EP1590034B1 (en) | 2002-10-07 | 2014-05-14 | Biovalve Technologies, Inc. | Microneedle array patch |
WO2005040338A2 (en) | 2003-05-21 | 2005-05-06 | The Scripps Research Institute | Constrained alkaloid immunogens and antibodies and uses thereof |
US7112678B2 (en) | 2003-11-17 | 2006-09-26 | North Carolina State University | Regiospecific synthesis of nicotine derivatives |
WO2005094526A2 (en) | 2004-03-24 | 2005-10-13 | Corium International, Inc. | Transdermal delivery device |
US20060111271A1 (en) | 2004-11-24 | 2006-05-25 | Cerny Erich H | Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements |
WO2006138719A2 (en) | 2005-06-17 | 2006-12-28 | Georgia Tech Research Corporation | Coated microstructures and method of manufacture thereof |
EP1849780A1 (en) | 2006-04-21 | 2007-10-31 | De Staat der Nederlanden, vert. door de minister van VWS | Vaccine against nicotine addiction |
EP2664323B1 (en) | 2007-04-16 | 2020-07-29 | Corium, Inc. | Solvent-cast microneedle arrays containing active |
WO2010056922A2 (en) | 2008-11-12 | 2010-05-20 | Kythera Biopharmaceuticals, Inc. | Systems and methods for delivery of biologically active agents |
WO2011031327A2 (en) | 2009-09-14 | 2011-03-17 | The Scripps Research Institute | Nicotine haptens, immunoconjugates and their uses |
-
2011
- 2011-06-01 TW TW100119221A patent/TWI455722B/zh not_active IP Right Cessation
- 2011-06-01 TW TW103125297A patent/TWI578997B/zh not_active IP Right Cessation
- 2011-06-02 US US13/151,590 patent/US8980276B2/en not_active Expired - Fee Related
- 2011-06-03 RU RU2012153061/04A patent/RU2574032C2/ru not_active IP Right Cessation
- 2011-06-03 KR KR1020137000151A patent/KR101429413B1/ko not_active IP Right Cessation
- 2011-06-03 AR ARP110101931A patent/AR081299A1/es unknown
- 2011-06-03 PE PE2012002273A patent/PE20130232A1/es not_active Application Discontinuation
- 2011-06-03 EP EP11728679.9A patent/EP2575893A1/en not_active Withdrawn
- 2011-06-03 JP JP2013513036A patent/JP5723976B2/ja not_active Expired - Fee Related
- 2011-06-03 MY MYPI2012005086A patent/MY158200A/en unknown
- 2011-06-03 MX MX2012014025A patent/MX342680B/es active IP Right Grant
- 2011-06-03 SG SG2012087540A patent/SG186090A1/en unknown
- 2011-06-03 NZ NZ603819A patent/NZ603819A/en not_active IP Right Cessation
- 2011-06-03 AU AU2011262221A patent/AU2011262221B2/en not_active Ceased
- 2011-06-03 CN CN201180027358.8A patent/CN102933237B/zh not_active Expired - Fee Related
- 2011-06-03 WO PCT/IB2011/052446 patent/WO2011151807A1/en active Application Filing
- 2011-06-03 CN CN201510242271.2A patent/CN104945374A/zh active Pending
- 2011-06-03 BR BR112012031360A patent/BR112012031360A2/pt not_active IP Right Cessation
- 2011-06-03 CA CA2800882A patent/CA2800882C/en not_active Expired - Fee Related
-
2012
- 2012-11-26 IL IL223279A patent/IL223279A0/en active IP Right Grant
- 2012-12-04 CO CO12220154A patent/CO6650413A2/es unknown
-
2013
- 2013-01-03 ZA ZA2013/00079A patent/ZA201300079B/en unknown
- 2013-08-13 HK HK13109500.9A patent/HK1182029A1/xx not_active IP Right Cessation
-
2015
- 2015-02-05 US US14/615,123 patent/US20150157708A1/en not_active Abandoned
- 2015-03-30 JP JP2015068524A patent/JP6047611B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-24 HK HK16102070.1A patent/HK1214250A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1214250A1 (zh) | 用於預防或治療煙碱成癮的綴合物 | |
IL225471A0 (en) | Preparations and methods for the prevention and treatment of cancer | |
EP2740793A4 (en) | MEDICINAL PREPARATION FOR CANCER TREATMENT AND / OR PREVENTION | |
AP3544A (en) | Compounds for the treatment of addiction | |
GB0810850D0 (en) | Tobacco treatment | |
LT3124610T (lt) | Hbv gydymas | |
ZA201107447B (en) | Treated tobacco | |
ZA201200843B (en) | Sogma ligands for the prevention or treatment of pain induced by chemotherapy | |
EP2558085A4 (en) | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CANCER | |
SG2014014724A (en) | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS | |
IL225371A0 (en) | Focoxim conjugates are useful for the treatment of pathologies related to 90hsp | |
IL214349A0 (en) | Compositions and methods for the treatment of cancer | |
EP2611440A4 (en) | TREATMENT AGAINST COCAINOMANIA | |
EP2437738A4 (en) | METHOD AND COMPOSITIONS FOR CANCER TREATMENT | |
ZA201007362B (en) | Conjugates for the treatment of mesothelioma | |
EP2536436A4 (en) | ANTIMIR-451 FOR THE TREATMENT OF POLYCYTHEMICS | |
EP2411031A4 (en) | Methods and compositions for the treatment of cancer | |
PL2608685T3 (pl) | Urządzenie do obróbki tytoniu | |
HK1175072A1 (en) | 2-aminoindole compounds and methods for the treatment of malaria 2- | |
IL223219A0 (en) | Flufenoxine derivatives for the treatment and prevention of amiloyd pathologies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190605 |